更新于：2024-12-17
Pazufloxacin Mesilate
甲磺酸帕珠沙星
更新于：2024-12-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2002-04-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H19FN2O7S |
InChIKeyUDHGFPATQWQARM-FJXQXJEOSA-N |
CAS号163680-77-1 |
关联
11
项与 甲磺酸帕珠沙星 相关的临床试验Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%.
A Phase I，Pazufloxacin Mesilate Ear Drops in Patients With Chronic Suppurative Otitis Media
甲磺酸帕珠沙星滴耳液在慢性化脓性中耳炎患者中单次给药的I期临床试验
100 项与 甲磺酸帕珠沙星 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸帕珠沙星 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸帕珠沙星 相关的专利（医药）
登录后查看更多信息
164
项与 甲磺酸帕珠沙星 相关的文献（医药）2023-01-01Journal of clinical laboratory analysis
Article
作者: Tatsuta, Ryosuke ; Suzuki, Yosuke ; Yasuda, Norihisa ; Goto, Koji ; Kitano, Takaaki ; Ohchi, Yoshifumi ; Tanaka, Ryota ; Itoh, Hiroki ; Kai, Makoto
Abstract:
Background:
Since severe infections frequently cause acute kidney injury (AKI), continuous renal replacement therapy (CRRT) is often initiated for regulation of inflammatory mediators and renal support. Thus, it is necessary to decide the antibiotic dosage considering the CRRT clearance in addition to residual renal function. Some of the hemofilters used in CRRT are known to adsorb antibiotics, and clearance of antibiotics may differ depending on the adsorptive characteristics of hemofilters. Although assay systems for blood and CRRT filtrate concentrations are required, no method for measuring antibiotics concentrations in filtrate has been reported. We developed a UHPLC–MS/MS method for simultaneous quantification of antibiotics commonly used in ICU, comprising carbapenems [doripenem (DRPM) and meropenem (MEPM)], quinolones [ciprofloxacin (CPFX), levofloxacin (LVFX) and pazufloxacin (PZFX)] and anti‐MRSA agents [linezolid (LZD), and tedizolid (TZD)] in CRRT filtrate samples.
Methods:
Filtrate samples were pretreated by protein precipitation. The analytes were separated with an ACQUITY UHPLC CSH C18 column under a gradient mobile phase consisting of water and acetonitrile containing 0.1% formic acid and 2 mM ammonium formate.
Results:
The method showed good linearity over wide ranges. Within‐batch and batch‐to‐batch accuracy and precision for each drug fulfilled the criteria of the US Food and Drug Administration guidance. The recovery rate was more than 87.20%. Matrix effect ranged from 99.57% to 115.60%. Recovery rate and matrix effect did not differ remarkably between quality control samples at different concentrations.
Conclusion:
This is the first report of a simultaneous quantification method of multiple antibiotics in filtrate of CRRT circuit.
2022-04-19Environmental science & technology1区 · 环境科学与生态学
Interface Engineering of Co(OH)2 Nanosheets Growing on the KNbO3 Perovskite Based on Electronic Structure Modulation for Enhanced Peroxymonosulfate Activation
1区 · 环境科学与生态学
Article
作者: Huang, Taobo ; Liu, Wen ; Yang, Xiaoyong ; Yang, Xudong ; Qi, Juanjuan ; Pan, Po-Yueh ; Wang, Chong-Chen
Material-enhanced heterogonous peroxymonosulfate (PMS) activation on emerging organic pollutant degradation has attracted intensive attention, and a challenge is the electron transfer efficiency from material to PMS for radical production. Herein, an interface architecture of Co(OH)2 nanosheets growing on the KNbO3 perovskite [Co(OH)2/KNbO3] was developed, which showed high catalytic activity in PMS activation. A high reaction rate constant (k1) of 0.631 min-1 and complete removal of pazufloxacin within 5 min were achieved. X-ray photoelectron spectroscopy, X-ray absorption near edge structure spectra, and density functional theory (DFT) calculations revealed the successful construction of the material interface and modulated electronic structure for Co(OH)2/KNbO3, resulting in the hole accumulation on Co(OH)2 and electron accumulation on KNbO3. Bader topological analysis on charge density distribution further indicates that the occupations of Co-3d and O-2p orbitals in Co(OH)2/KNbO3 are pushed above the Fermi level to form antibonding states (σ*), leading to high chemisorption affinity to PMS. In addition, more reactive Co(II) with the closer d-band center to the Fermi level results in higher electron transfer efficiency and lower decomposition energy of PMS to SO4•-. Moreover, the reactive sites of pazufloxacin for SO4•- attack were precisely identified based on DFT calculation on the Fukui index. The pazufloxacin pathways proceeded as decarboxylation, nitroheterocyclic ring opening reaction, defluorination, and hydroxylation. This work can provide a potential route in developing advanced catalysts based on manipulation of the interface and electronic structure for enhanced Fenton-like reaction such as PMS activation.
2021-12-01International journal of toxicology4区 · 医学
Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database
4区 · 医学
Article
作者: Abe, Yasuharu ; Yamamoto, Takanori ; Asai, Yuki
Drug-induced thrombocytopenia (DITP) can be triggered by antibiotics; however, the details remain unclear. Here, we evaluated the expression profiles of DITP using the Japanese Adverse Drug Event Report (JADER) database. We analyzed reports of DITP between April 2004 and January 2021 from the JADER database. The reporting odds ratio (ROR) and 95% confidence interval (CI) were used to detect DITP signals. Factors thought to affect DITP, such as male sex and an age of at least 60 years, were added as covariates. We evaluated the time-to-onset profile and hazard type using the Weibull shape parameter. The JADER database contained 1,048,576 reports. Twelve of 60 antibiotics showed signals for DITP; the RORs (95% CIs) for ampicillin/sulbactam, ceftazidime, cefozopran, ciprofloxacin, fluconazole, fos-fluconazole, linezolid, pazufloxacin, piperacillin/tazobactam, teicoplanin, trimethoprim/sulfamethoxazole, and voriconazole were 1.75 (1.41-2.16), 1.77 (1.42-2.18), 1.35 (1.06-1.72), 2.56 (2.19-2.98), 1.93 (1.67-2.23), 2.08 (1.76-2.46), 5.29 (2.73-9.60), 1.92 (1.51-2.41), 1.54 (1.05-2.19), 1.47 (1.16-1.84), 1.92 (1.73-2.14), and 2.32 (1.59-3.30), respectively. In multiple logistic regression analysis, 7 and 6 antibiotics were detected for the factors age and male sex, respectively. The median times-to-onset of DITP for ciprofloxacin (oral treatment), fluconazole, linezolid, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole were 91, 91, 11.5, 10, and 9 days, respectively. Furthermore, the 95% CI of the Weibull shape parameter β for these antibiotics was above and excluded 1, indicating that the antibiotics were the wear out failure type. We revealed the expression profiles of DITP following treatment with 12 antibiotics.
100 项与 甲磺酸帕珠沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 中国 | 2004-01-01 | |
| 细菌感染 | 日本 | 2002-04-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性化脓性中耳炎 | 临床1期 | 中国 | 2018-07-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 46 | (PRO-157) | 繭糧範餘構衊範齋積顧(鏇繭獵淵蓋衊蓋襯顧觸) = 築築築築築夢蓋觸鬱遞 餘膚醖廠衊築衊夢艱衊 (製膚積選築艱鹹築獵齋, 觸夢遞鬱衊夢積簾襯醖 ~ 鬱鏇鹽廠範選築夢築艱) 更多 | - | 2021-08-24 | ||
(Zymar) | 繭糧範餘構衊範齋積顧(鏇繭獵淵蓋衊蓋襯顧觸) = 繭構鏇夢餘鹹範繭淵衊 餘膚醖廠衊築衊夢艱衊 (製膚積選築艱鹹築獵齋, 艱蓋廠築淵鹹齋製鬱顧 ~ 繭夢壓遞繭夢鑰齋顧夢) 更多 | ||||||
临床2期 | 150 | (PRO-157 BID (2 Times Per Day)) | 膚醖遞遞鏇獵選鬱繭構(艱壓鏇醖獵遞簾鬱蓋壓) = 壓觸襯廠憲廠鏇繭壓繭 艱窪膚遞膚糧糧夢顧選 (願網鬱構網構蓋憲憲鏇, 積顧餘鏇夢鏇蓋構願網 ~ 壓淵鏇鑰壓製製壓鏇醖) 更多 | - | 2019-02-15 | ||
(PRO-157 TID (3 Times Per Day)) | 膚醖遞遞鏇獵選鬱繭構(艱壓鏇醖獵遞簾鬱蓋壓) = 壓築蓋築壓壓鹽鑰製艱 艱窪膚遞膚糧糧夢顧選 (願網鬱構網構蓋憲憲鏇, 鏇觸壓積鏇齋餘壓淵膚 ~ 餘鏇遞襯鏇廠糧繭鑰艱) 更多 | ||||||
临床2期 | 300 | Pazufloxacin 0.09% BID | 衊繭醖顧衊蓋繭艱觸範(憲憲觸顧構襯醖構廠膚) = 鹽膚衊網網觸繭壓簾願 範蓋觸醖範選範糧鹹淵 (選鑰憲膚遞範廠鬱繭襯 ) | 积极 | 2017-05-07 | ||
Pazufloxacin 0.09% TID | 衊繭醖顧衊蓋繭艱觸範(憲憲觸顧構襯醖構廠膚) = 鏇壓齋齋鹹觸鑰選願網 範蓋觸醖範選範糧鹹淵 (選鑰憲膚遞範廠鬱繭襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用